The association between levels of tissue inhibitor of metalloproteinase-1 with acute heart failure and left ventricular dysfunction in patients with st elevation myocardial infarction treated by primary percutaneous coronary intervention

Genetic Testing and Molecular Biomarkers

Volumn 16, Issue 10, 2012, Pages 1172-1178

  Goldbergova, Monika Pavkova ^a   Parenica, Jiri ^b,c   Jarkovsky, Jiri ^a   Kala, Petr ^b   Poloczek, Martin ^b   Manousek, Jan ^b   Kluz, Krystyna ^b,d   Kubkova, Lenka ^b   Littnerova, Simona ^a   Tesak, Martin ^b   Toman, Ondrej ^b   Pavek, Nikolas ^a   Cermakova, Zdenka ^b   Tomandl, Josef ^a   Vasku, Anna ^a   Spinar, Jindrich ^b,c  

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^d Podlesí Hospital a s T inec   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ACUTE HEART FAILURE; ADULT; ARTICLE; BLOOD SAMPLING; DISEASE ASSOCIATION; EXON; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYMPTOM; X CHROMOSOME;

ADULT; AGED; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; POLYMORPHISM, GENETIC; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84867517308     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2012.0120     Document Type: Article

References (18)

1. Anderson CL, Brown CJ (2005) Epigenetic predisposition to expression of TIMP1 from the human inactive X chromosome. BMC Genetics 6:48.
2. Baicu CF, Stroud JD, Livesay VA, et al. (2003) Changes in extracellular collagen matrix alter myocardial systolic performance. Am J Physiol Heart Circ Physiol 284:H122-H132.
3. Docherty AJP, Lyons A, Smith BJ, et al. (1985) Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature 318:66-69.
4. Furenes EB, Arnesen H, Solheim S, et al. (2009) The profile of circulating metalloproteinases after PCI in patients with acute myocardial infarction or stable angina. Thromb Res 124:560-564.
5. Giancotti FG, Ruoslahti E (1999) Integrin Signaling. Science 285:1028-1033.
6. Hinterseher I, Krex D, Kuhlisch E, et al. (2007) Tissue inhibitor of metalloproteinase-1 (TIMP-1) polymorphisms in a caucasian population with abdominal aortic aneurysm. World J Surg 31:2248-2254.
7. Ikonomidis JS, Hendrick JW, Parkhurst AM, et al. (2005) Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition. Am J Physiol Heart Circ Physiol 288:H149-H158.
8. Jayasankar V, Woo YJ, Bish LT, et al. (2004) Inhibition of matrix metalloproteinase activity by TIMP-1 gene transfer effectively treats ischemic cardiomyopathy. Circulation 110:180-186.
9. Kanauchi M, Nishioka H, Nakashima Y, et al. (1996) Role of tissue inhibitors of metalloproteinase in diabetic nephropathy. Nippon Jinzo Gakki Shi 38:124-128.
10. Kelly D, Khan SQ, Thompson M, et al. (2008) Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloprotei-nase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. Eur Heart J 29:2116-2124.
11. Kelly D, Squire IB, Khan SQ, et al. (2010) Usefulness of plasma tissue inhibitors of metalloproteinases as markers of prognosis after acute myocardial infarction. Am J Cardiol 106:477-482.
12. López-Cuenca A, Marín F, Roldán V, et al. (2010) Effects of ator-vastatin 80 mg daily on indices of matrix remodelling in "high-risk" patients with ischemic heart disease. Int J Cardiol 139:95-97.
13. Nagase H, Woessner JF (1999) Matrix Metalloproteinases. J Biol Chem 274:21491-21494.
14. Nilsson L, Hallén J, Atar D, et al. (2012) Early measurements of plasma matrix metalloproteinase-2 predict infarct size and ventricular dysfunction in ST-elevation myocardial infarction. Heart 98:31-36.
15. Tyagi SC (1993) Direct extraction and estimation of collage-nase(s) activity by zymography in microquantities of rat myocardium and uterus. Clin Biochem 26:191-198.
16. Webb CS, Bonnema DD, Ahmed SH, et al. (2006) Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation 114:1020-1027.
17. Weir RAP, Clements S, Steedman T, et al. (2011) Plasma TIMP-4 predicts left ventricular remodeling after acute myocardial infarction. J Card Fail 17:465-471.
18. West MJ, Nestel PJ, Kirby AC, et al. (2008) The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study. Eur Heart J 29:923-931.